Abstract Purpose: Hyperglycaemia is common in the critically ill. The objectives of this study were to determine the prevalence of critical illness-associated hyperglycaemia (CIAH) and recognised and unrecognised diabetes in the critically ill as well as to evaluate the impact of premorbid glycaemia on the association between acute hyperglycaemia and mortality. Methods: In 1,000 consecutively admitted patients we prospectively measured glycated haemoglobin (HbA 1c ) on admission, and blood glucose concentrations during the 48 h after admission, to the intensive care unit. Patients with blood glucose C7.0 mmol/l when fasting or C11.1 mmol/l during feeding were deemed hyperglycaemic. Patients with acute hyperglycaemia and HbA 1c \6.5 % (48 mmol/mol) were categorised as 'CIAH', those with known diabetes as 'recognised diabetes', and those with HbA 1c C6.5 % but no previous diagnosis of diabetes as 'unrecognised diabetes'. The remainder were classified as 'normoglycaemic'. Hospital mortality, HbA 1c and acute peak glycaemia were assessed using a logistic regression model. Results: Of 1,000 patients, 498 (49.8 %) had CIAH, 220 (22 %) had recognised diabetes, 55 (5.5 %) had unrecognised diabetes and 227 (22.7 %) were normoglycaemic. The risk of death increased by approximately 20 % for each increase in acute glycaemia of 1 mmol/l in patients with CIAH and those with diabetes and HbA 1c levels \7 % (53 mmol/mol), but not in patients with diabetes and HbA 1c C7 %. This association was lost when adjusted for severity of illness. Conclusions: Critical illness-associated hyperglycaemia is the most frequent cause of hyperglycaemia in the critically ill. Peak glucose concentrations during critical illness are associated with increased mortality in patients with adequate premorbid glycaemic control, but not in patients with premorbid hyperglycaemia. Optimal glucose thresholds in the critically ill may, therefore, be affected by premorbid glycaemia.
Introduction
Hyperglycaemia is common in the critically ill and may be secondary to either diabetes (recognised or not) or critical illness-associated hyperglycaemia (CIAH) [1, 2] . The latter condition refers to patients who have normal glucose tolerance following resolution of their acute illness. However, there is limited information about the respective prevalence of these conditions [2] [3] [4] , with the majority of studies only assessing acute glycaemia and thus failing to discriminate between hyperglycaemia associated with unrecognised diabetes and true CIAH.
Such categorisation may be important as retrospective data suggest that the benefit in treating hyperglycaemia during critical illness may be diminished in patients with known diabetes [5] [6] [7] [8] [9] [10] . Furthermore, in a retrospective observational study using glycated haemoglobin (HbA 1c ) measured in the 3 months prior to ICU admission as a marker of premorbid glycaemia, it was reported that acute hyperglycaemia was associated with a reduction, rather than an increase, in mortality in patients with 'insufficiently controlled' diabetes [7] . Given that in CIAH the magnitude of hyperglycaemia is associated with increased mortality [7, 11] , it is plausible that the impact of acute hyperglycaemia on outcome is dependent on premorbid glycaemia. In this regard, a recent position statement from the European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA) emphasised that targets for chronic glucose control (HbA 1c ) in ambulant patients with type 2 diabetes should be individualised [12] . However, the concept that during critical illness acute glycaemic targets should be individualised, based on premorbid glycaemia (HbA 1c ), has apparently not been formally considered [13, 14] .
Accordingly, in a cohort of critically ill patients, we aimed to determine the prevalence of CIAH and of recognised and unrecognised diabetes, and to evaluate prospectively the impact of premorbid glycaemia on the association between acute hyperglycaemia and mortality. The blood glucose thresholds for CIAH are based on the American Diabetes Association (ADA) Diabetes in Hospitals Writing Committee guidelines that state that thresholds used in health, that is fasting plasma glucose C7.0 mmol/l and/or random plasma glucose C11.0 mmol/l, are appropriate for use in hospitalised patients and allow standardisation in this area [15] .
Patients and methods

Patients
We performed a prospective single-centre observational study in a general intensive care unit (ICU) and studied 1,000 consecutively admitted patients aged C18 years who were admitted for C24 h. The study was conducted between August 2012 and June 2013 at the Royal Adelaide Hospital ICU. The Royal Adelaide Hospital is a 680-bed quaternary university-affiliated hospital and is one of two centres for trauma and neurosurgical services in the state of South Australia. It is the only centre for burns and spinal injuries in the state. The ICU has 24 beds and admits all medical and surgical patients requiring organ support, with the exception of those admitted to the high dependency and cardiothoracic surgical units that admit patients not requiring organ support and post cardiac surgery, respectively. Patients admitted to the last two locations were not included in this analysis.
Protocol
This protocol was approved by the Research Ethics Committee of the Royal Adelaide Hospital, with the need for informed consent waived. It was registered with the Australian New Zealand Clinical Trials Registry (http://www.anzctr.com.au; ACTRN12611000973910). We recorded age, body mass index (BMI), administration of catecholamines and corticosteroids during the initial 48 h of admission. We also obtained information on the acute physiology and chronic health evaluation (APACHE) II score and hospital outcomes from the hospital electronic data repository. In all patients insulin was administered by continuous intravenous infusion according to an algorithm to target a blood glucose of 6.0-10.0 mmol/l, such that all patients with a blood glucose level [10 mmol/l were commenced on intravenous Abbreviations insulin ( Supplementary Fig. 2 ) [16] . On the first available blood sample after ICU admission, we measured glycated haemoglobin (HbA 1c ) as a marker of premorbid glycaemia. Blood was collected into EDTA tubes and HbA 1c levels measured using high-performance liquid chromatography [Biorad HPLC variant II turbo, California, USA (Qc: 2.44 %)]. We also collated all blood glucose concentrations during the initial 48 h of admission with the peak blood glucose concentration recorded during the first 48 h of admission used to define acute glycaemia. Blood gas analysers (Radiometer ABL800 Series Flex Q, Denmark) or bedside glucometers (Optium Xceed; Abbott Laboratories, Bedford, MA, USA) were used to measure blood glucose. Blood glucose was measured every hour unless it was between 6 and 10 mmol/l and insulin administration was unchanged from the previous measurement when the interval between measurements was extended to every 2 h ( Supplementary Fig. 2 ).
Data analysis
We classified patients into the following groups according to their HbA 1c and peak blood glucose in the first 48 h: CIAH, 'recognised diabetes', 'unrecognised diabetes' and 'normoglycaemia'. CIAH was defined by HbA 1c \6.5 % (48 mmol/mol) and any 'fasting' (i.e. patients not receiving enteral or intravenous nutrition) blood glucose C7.0 mmol/l and/or random blood glucose C11.1 mmol/l during feeding [15, 17] .
We identified 'recognised diabetes' using the hospital case notes and history provided by family members. Any previous diagnosis of glucose intolerance (apart from gestational diabetes) was considered as recognised diabetes. We defined 'unrecognised diabetes' as an admission HbA 1c C6.5 % in the absence of a history of glucose intolerance. The latter was confirmed by contacting the patient's family physician.
We defined 'normoglycaemia' as the combination of an admission HbA 1c \6.5 %, 'fasting' blood glucose \7.0 mmol/l and random blood glucose \11.1 mmol/l [15, 17] .
On the basis of the current ADA/EASD position statement, we categorised patients with diabetes according to their premorbid glycaemia as 'stringently controlled' [HbA 1c \6 % (42 mmol/mol)], 'adequately controlled' [6 % B HbA 1c \ 7 % (53 mmol/mol)], and 'insufficiently controlled' (HbA 1c C7 %) [12] .
Statistical analysis
Data are presented as mean (SD) or median (range) as appropriate and were evaluated using one-way analysis of variance (ANOVA), with Tukey post hoc tests for age, BMI, APACHE II, HbA 1c and peak blood glucose in the first 48 h. ICU and hospital length of stay were analysed using non-parametric Kruskall-Wallis tests with post hoc Mann-Whitney tests and Bonferroni-Holm adjustment. Chi-squared tests were used to assess catecholamine use, steroid use and mortality, with post hoc Bonferroni-Holm adjustment for multiple comparisons. Patients still in ICU or hospital at the time of follow-up were censored at their observed length of stay. The outcome of hospital mortality was assessed in relation to HbA 1c and peak blood glucose using a logistic regression model. Predictors in both models were HbA 1c -assigned as categorical data in three bands: \6 %; 6 % B HbA 1c \ 7 %; and HbA 1c C7 %-and peak blood glucose concentration as a continuous variable. The interaction term (peak glucose*HbA 1c ) was used for the three categories. The Hosmer and Lemeshow goodness of fit test was used to evaluate the risk of mortality determined using the logistic regression model. Data were also analysed post hoc for potential confounding including age, APACHE II score and type of admission (medical or surgical). A P value of 0.05 was used for significance. Analyses were run using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) by an independent biostatistician.
Results
We studied 1,000 patients (646 men), with a mean age of 55 (18) years, BMI 27.4 (7) kg/m 2 and an APACHE II score of 18 (7.6). The median hospital length of stay was 11.8 (1-258) days, with 145 (14.5 %) patients dying in hospital and 16 patients still in hospital at the time of analysis. Patients were admitted with a primary disorder of respiratory (22.8 %), trauma (18.6 %), neurological (17 %), gastrointestinal (11 %), cardiovascular (9.9 %), sepsis (6.7 %), metabolic (6.2 %), haematologic (2.9 %), renal/genitourinary (2.5 %), and musculoskeletal/skin (2.3 %). Overall median HbA 1c was 5.7 (3.8-16) % [39 (18-151) mmol/mol] and median peak blood glucose 9.4 (3.2-38.8) mmol/l.
Prevalence of CIAH, recognised and unrecognised diabetes, and normoglycaemia
In total, 498 (49.8 %) patients had CIAH, 220 (22 %) had 'recognised diabetes' (5 % with known type 1), 55 (5.5 %) had 'unrecognised diabetes' (all of whom were type 2), and only 227 (22.7 %) were 'normoglycaemic'.
Of the 275 patients with either recognised or unrecognised diabetes, 146 (53 %) had 'stringently' or 'adequately controlled' diabetes and 129 (47 %) had 'insufficiently controlled' diabetes. Of the 220 patients with recognised diabetes, the treatment of hyperglycaemia prior to critical illness included oral medication in 70 (32 %), diet alone in 56 (25 %), insulin in 48 (22 %), and both oral medications and insulin in 18 (8 %) patients. We were unable to determine pre-existing therapy in 28 (13 %) patients.
Both recognised and unrecognised diabetes were associated with greater peak glucose concentrations than CIAH (Table 1) . Patients with diabetes also had higher APACHE II scores, were older, and weighed more than CIAH or normoglycaemic patients (Table 1) . Normoglycaemic patients required less exogenous catecholamine support, had shorter admissions, and had fewer deaths compared to patients with diabetes (recognised and unrecognised) or CIAH ( Table 1 ). There were no significant differences in catecholamine use, length of stay, admission category (medical vs surgical) or mortality between patients with diabetes (recognised and unrecognised) and CIAH (Table 1) .
Relationships between premorbid glycaemia, acute glycaemia and outcome Nine hundred and ninety eight patients had data available for logistic regression analysis. There was a significant interaction between acute glycaemia, HbA 1c and mortality (P = 0.04), such that, in patients without diabetes and those with 'stringently controlled' diabetes, the risk of death increased by 20 % (95 % CI 1.12, 1.28) for each increase in acute glycaemia of 1 mmol/l (P \ 0.001; Fig. 1 ). There was also a significant relationship between mortality and acute glycaemia in patients with 'adequately controlled' diabetes (P = 0.003; Fig. 1 ). In contrast, among patients with 'insufficiently controlled' diabetes (i.e. chronic premorbid hyperglycaemia) there was no significant relationship between mortality and acute glycaemia (P = 0.95; Fig. 1 ) such that the risk of death did not change, even when peak glucose concentrations increased above 15 mmol/l. The logistic regression model was an adequate fit (P = 0.29). When data were analysed adjusting for potential confounders, the association between acute peak glucose and mortality was no longer significant. The adjusted model was interrogated for the significance of each individual term and APACHE II was the only variable that indicated an independent association with mortality [OR 1.16, CI 1.13-1.20 (P \ 0.001)] (Supplementary Fig. 1 ).
Patients with 'insufficiently controlled' diabetes were comparable in age, BMI, admission category (medical vs surgical) and severity of illness to those with 'adequately controlled' diabetes (Table 2 ). Despite significantly elevated peak blood glucose levels in the former group, ICU and hospital mortality as well of length of stay were not different when compared to the 'adequately controlled' patients ( Table 2) .
Discussion
In this prospective observational study, critical illnessassociated hyperglycaemia (CIAH) occurred in up to 50 % of patients and while diabetes occurred in 27.5 % of the cohort, this was apparently unrecognised in only 5.5 %. While acute hyperglycaemia was associated with increased mortality in patients without diabetes and in those with 'adequately controlled' diabetes, there was no association in patients with 'insufficiently controlled' diabetes (i.e. chronic premorbid hyperglycaemia), even when glucose concentrations exceeded 15 mmol/l. After adjusting for age, BMI, APACHE II and admission type, the predicted mortality curves were no longer significant for patients with HbA 1c \6 % and between 6 and 7 %, probably reflecting the dominant association between APACHE II and mortality. Given observations from prospective multi-centre interventional studies of larger sample populations, marked hyperglycaemia should still be considered as harmful in patients without pre-existing diabetes, and in patients with 'stringently' or 'adequately controlled' diabetes [16, 18, 19] .
Two previous studies have provided data related to the prevalence of unrecognised diabetes in the critically ill. Cely and colleagues [3] enrolled a sample of 75 patients admitted to a single medical ICU and, using HbA 1c C6.5 %, reported that 12 % of patients had unrecognised diabetes. Gornik and colleagues [20] performed a 75 g oral glucose tolerance test (OGTT) at 4-6 weeks after discharge in 1,105 critically ill patients and reported that unrecognised type 2 diabetes was evident in approximately 15 %. In ambulant populations, diabetes can be determined by using elevated fasting plasma glucose, 2 h glucose concentrations during an OGTT, or HbA 1c [21] . However use of fasting plasma glucose in the critically ill is impractical and the performance of the OGTT has clear limitations because gastric emptying, which is a major determinant of the glycaemic response [22] , is often markedly impaired in this group [23] .
Previous epidemiological studies in Australia suggest that 7 % of the population aged [25 years has diabetes with about half of these being unrecognised [24] . It is plausible that unrecognised diabetes predisposes to severe illness and, on the basis of the studies by Cely and Gornik, we anticipated that the prevalence of unrecognised diabetes would be 10-15 % [2] . However, we found that the prevalence of unrecognised diabetes (5.5 %) was similar to that of the ambulant Australian population [24] .
Arguably, the most accurate estimate of the prevalence of CIAH prior to this study was derived from the NICE-SUGAR study-in which approximately 60 % of nondiabetic patients had at least one blood glucose measurement [10 mmol/l [16] . Limitations of using NICE-SUGAR data for this purpose are that HbA 1c was not measured and the World Health Organisation (WHO) threshold for 'postprandial' hyperglycaemia is slightly greater at 11.1 mmol/l [17] . Accordingly, patients with unrecognised type 2 diabetes were not identified and CIAH may have been overdiagnosed [2] . Our observations are consistent with these perceptions.
While recently there has been a shift in focus to individualizing HbA 1c targets for ambulant patients with type 2 diabetes [12] , the hypothesis that premorbid glycaemic control may modulate the response to hyperglycaemia during critical illness has not been tested [2, 13] . Previous studies have reported strong associations between hyperglycaemia and mortality in patients admitted with acute myocardial infarction [25] and heterogenous groups of critically ill patients [5, 7, 10, 11, 26] , with the strength of the relationship attenuated, or absent, in those patients with known diabetes [5, 9, 11, 25] . However, a limitation of all these studies is that patients with unrecognised diabetes were not identified and, therefore, were categorised as not having diabetes [1, 2] . Moreover, grouping patients with diabetes as a homogeneous cohort may well be flawed [2] , particularly as retrospective data suggest that hyperglycaemia in patients with 'insufficiently controlled' type 2 diabetes could be less harmful, and potentially may even be protective [27] . In their aggregate, these data provide a strong justification for future prospective, randomised studies to determine whether the optimal acute glucose range in critically ill patients should be individualised on the basis of their premorbid glycaemic status (HbA 1c ) [2] .
Our study has several strengths. We prospectively measured HbA 1c levels in a large, heterogeneous cohort of consecutively admitted patients, limiting the likelihood of bias and type 2 error. Furthermore, by contacting the patient's family physician, we confirmed the categorisation of patients as 'unrecognised diabetes'. On the basis of the median APACHE II score our cohort was representative of a critically ill population and by excluding patients admitted to the cardiac care unit following acute myocardial infarction or cardiac surgery we minimised the bias from these subgroups [28, 29] . There are, however, inherent limitations related to a single-centre design with the potential for recruitment bias, based on the prevalence of diabetes in the surrounding community [30] . We did not exclude patients with haemoglobinopathies, iron deficiency anaemia, or those who had received blood transfusions. Although these conditions are known to affect the measured HbA 1c [31, 32] and occur in the critically ill, we determined the HbA 1c on the first available blood sample to limit the likelihood of erroneous measurements.
A further limitation is that peak blood glucose level in the first 48 h was the sole metric of glycaemic control. While glycaemic variability, mean blood glucose and hypoglycaemic events all have the capacity to influence outcome [25, 33] blood glucose concentrations within the first 24 h are predictive of overall glycaemic control throughout ICU admission [34] . Furthermore, peak blood glucose is the trigger for intervention and is, therefore, clinically relevant. The influence of chronic hyperglycaemia on the other domains of glycaemic control during critical illness warrants further investigation.
In addition, we only measured deaths that occurred in hospital, and it is possible that the harm associated with acute glycaemia may become greater following discharge [16] . On the basis of previous recommendations [27] we categorised premorbid glucose control (HbA 1c ) into three groups. However, the interaction between acute hyperglycaemia and premorbid glycaemia may be far more complex with outcomes differing between patients at the extremes within the 'insufficiently controlled' range, i.e. outcomes in patients with HbA 1c of 7.1 and 10 % may differ. Larger cohorts are required to further evaluate this relationship, as well as the interactions between diagnostic category, illness severity, catecholamine and steroid use. Finally, while it appears that premorbid hyperglycaemia may modulate the association of acute hyperglycaemia with increased mortality, we cannot prove causality and can only speculate on mechanisms. There is biological plausibility that the sudden correction of chronic hyperglycaemia during acute illness may be harmful [27] and comparisons have been drawn with other fields of medicine in which there is a risk associated with the rapid correction of long-standing, abnormal physiological states (hypoxaemia, hyponatraemia, hypertension) [7] . A putative mechanism to account for these observations is that chronic hyperglycaemia is associated with adaptive changes at the cellular level resulting in relative neuroglycopenia [35] .
In conclusion, acute hyperglycaemia secondary to CIAH or diabetes (both recognised and unrecognised) occurs frequently in the critically ill and appears to have a complex relationship with mortality. In patients with CIAH and 'adequately controlled' diabetes, acute hyperglycaemia is associated with increased mortality, whereas in patients with 'insufficiently controlled' diabetes it is not. These data provide a strong justification for controlled studies targeting the impact of different acute glucose levels according to the degree of premorbid glycaemia.
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